Apremilast for psoriatic arthritis rejected by NICE

NICE had rejected the NHS use of apremilast (Otezla) alone or in combination for the treatment of active psoriatic arthritis when DMARDs are unsuitable.

NICE concluded that apremilast is clinically effective compared with no other treatment. However, when compared with TNF-alpha inhibitors, apremilast was the least clinically effective for treating psoriatic arthritis. Although some costs were saved by the use of apremilast, NICE concluded they were not sufficient to justify the health losses.

Further information
NICE technology appraisal TA372

Professor Carole Longson, Director of the Health Technology Evaluation Centre at NICE, explained  "there was not enough robust evidence demonstrating that apremilast slows progression of the disease compared to TNF-alpha inhibitors."

This follows a previous rejection by NICE, for the use of apremilast in moderate to severe plaque psoriasis.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Contraceptive shortages reported by manufacturers

Contraceptive shortages reported by manufacturers

Shortages of several contraceptives, including combined,...

Hormone Replacement Therapy (HRT)

Hormone Replacement Therapy (HRT)

Hormone doses and costs of HRT preparations.

Drug shortages - live tracker

Drug shortages - live tracker

Added: FemSeven Sequi and FemSeven Conti.
Use...

Last chance to register for the next Respiratory and Allergy Learning Series event

Last chance to register for the next Respiratory and Allergy Learning Series event

Join Dr Steve Holmes, who will be chairing the MIMS...